The browser you are using is not supported by this website. All versions of Internet Explorer are no longer supported, either by us or Microsoft (read more here:

Please use a modern browser to fully experience our website, such as the newest versions of Edge, Chrome, Firefox or Safari etc.

Tanja Stocks

Tanja Stocks

Project manager

Tanja Stocks

Dietary intake of acrylamide and epithelial ovarian cancer risk in the European Prospective Investigation into Cancer and Nutrition (EPIC) cohort.


  • Mireia Obón-Santacana
  • Petra H Peeters
  • Heinz Freisling
  • Laure Dossus
  • Francoise Clavel-Chapelon
  • Laura Baglietto
  • Helena Schock
  • Renée T Fortner
  • Heiner Boeing
  • Anne Tjonneland
  • Anja Olsen
  • Kim Overvad
  • Virginia Menéndez
  • Maria-Jose Sanchez
  • Nerea Larranaga
  • José María Huerta Castaño
  • Aurelio Barricarte
  • Kay-Tee Khaw
  • Nick Wareham
  • Ruth C Travis
  • Melissa A Merritt
  • Antonia Trichopoulou
  • Dimitrios Trichopoulos
  • Philippos Orfanos
  • Giovanna Masala
  • Sabina Sieri
  • Rosario Tumino
  • Paolo Vineis
  • Amalia Mattiello
  • H Bas Bueno-de-Mesquita
  • N Charlotte Onland-Moret
  • Elisabet Wirfält
  • Tanja Stocks
  • Annika Idahl
  • Eva Lundin
  • Guri Skeie
  • Inger T Gram
  • Elisabete Weiderpass
  • Elio Riboli
  • Eric J Duell

Summary, in English

Acrylamide, classified in 1994 by IARC as 'probably carcinogenic' to humans, was discovered in 2002 in some heat-treated, carbohydrate-rich foods. The association between dietary acrylamide intake and epithelial ovarian cancer risk (EOC) has been previously studied in one case-control and three prospective cohort studies which obtained inconsistent results, and could not further examine histological subtypes other than serous EOC. The present study was carried out in the European Prospective Investigation into Cancer and Nutrition (EPIC) sub-cohort of women (n=325,006). Multivariate Cox proportional hazards models were used to assess the association between questionnaire-based acrylamide intake and EOC risk. Acrylamide was energy-adjusted using the residual method, and was evaluated both as a continuous variable (per 10µg/day) and in quintiles; when subgroups by histological EOC subtypes were analyzed, acrylamide intake was evaluated in quartiles. During a mean follow-up of 11 years, 1,191 incident EOC cases were diagnosed. At baseline, the median acrylamide intake in EPIC was 21.3 μg/day. No associations, and no evidence for a dose-response were observed between energy-adjusted acrylamide intake and EOC risk (HR10µg/day:1.02, 95%CI:0.96-1.09; HRQ5vsQ1:0.97, 95%CI:0.76-1.23). No differences were seen when invasive EOC subtypes (582 serous, 118 endometrioid, and 79 mucinous tumors) were analyzed separately. This study did not provide evidence that acrylamide intake, based on food intake questionnaires, was associated with risk for EOC in EPIC. Additional studies with more reliable estimates of exposure based on biomarkers may be needed.


  • Nutrition Epidemiology
  • BioCARE: Biomarkers in Cancer Medicine improving Health Care, Education and Innovation
  • Diabetes - Cardiovascular Disease
  • EpiHealth: Epidemiology for Health

Publishing year







Cancer Epidemiology Biomarkers & Prevention





Document type

Journal article


American Association for Cancer Research


  • Cancer and Oncology



Research group

  • Nutrition Epidemiology
  • Diabetes - Cardiovascular Disease


  • ISSN: 1538-7755